Navigation Links
New medications show promise in treating drug-resistant prostate cancer
Date:4/7/2009

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

Of 30 men who received low doses of one the drugs in a multisite phase I/II trial designed to evaluate safety, 22 showed a sustained decline in the level of prostate specific antigen (PSA) in their blood. Phase III clinical trials are planned to evaluate the drug's effect on survival in a large group of patients with metastatic prostate cancer.

The drugs are second-generation antiandrogen therapies that prevent male hormones from stimulating growth of prostate cancer cells. The new compounds manufactured by the pharmaceutical company Medivation and known as MDV3100 and RD162 appear to work well even in prostate cells that have a heightened sensitivity to hormones. That heightened sensitivity makes prostate cancer cells resistant to existing antiandrogen therapies.

The drugs were discovered in the laboratory of Howard Hughes Medical Institute investigator Charles Sawyers at Memorial Sloan-Kettering Cancer Center in collaboration with chemist Michael Jung at UCLA. He and his colleagues described the development of the drugs and initial testing in an article posted online April 9, 2009, in Science Express, which provides electronic publication of selected Science articles in advance of print. Sawyers's team collaborated on the studies with researchers from the University of California Los Angeles, Oregon Health and Science University, University of Washington and Medivation.

About 186,000 new cases of prostate cancer are diagnosed each year in the United States. The male hormones testosterone and dihydrotestosterone -- also known as androgens -- spur the growth of prostate cells, and drugs that block the receptors for these hormones are the most common treatment for the disease in its advanced, metastatic stage. Antiandrogen drugs, such as bicalutamide, supp
'/>"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Device prevents potential errors in childrens medications
2. Study of successful drug targets could hasten development of new medications
3. Genetic variant mimics effect of heart failure medications
4. Hypertension and cholesterol medications present in water released into the St. Lawrence River
5. Innovative civil engineering application promises cleaner waters
6. New CPR promises better results by compressing abdomen, not Chest
7. Tiny tubes and rods show promise as catalysts, sunscreen
8. New genetic research into nicotine addiction shows promise for personalized treatment
9. Genetic ancestral testing cannot deliver on its promise, study warns
10. Sweet potato shines as new promise for small enterprise and hunger relief in developing countries
11. Summer-dormant tall fescue grass shows promise for pasture improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... By day, insects provide the white noise of the South, ... typical year, the Southern air hangs heavy from the humidity ... to more than 140 species of frogs, toads and salamanders, ... If the ponds and swamps are the auditorium for their ... Research and Monitoring Initiative, or ARMI, have front-row seats. ...
(Date:5/17/2013)... (Intelligent Cargo in Efficient and Sustainable Global Logistics Operations) ... improvement in the efficiency of intermodal loading systems and ... It comprises 29 European organisations with experience in the ... a budget totalling 17,000,000 and a duration of three ... specify and develop the semantic components and ontologies shared ...
(Date:5/16/2013)... MARC (Maximizing Access to Research Careers) Program has ... Society (ENDO) 95th Annual Meeting in San Francisco, ... meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage ... 2013 Annual Meeting. , Awards are given to ...
Breaking Biology News(10 mins):Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4New logistics services that will cut energy consumption and CO2 emissions 2
... what looks to be a nice piece of certified sustainable ... what you,re getting. Unfortunately, things aren,t always what they seem, ... eco-labeled Chilean sea bass and report their findings in the ... Press publication. "We found that, for fish purchased ...
... AUGUST 22, 2011, 3:00 PM U.S. EASTERN TIME) ... Academy of Sciences (PNAS) documents the success of ... business model to improve rural livelihoods while restoring local ... the program began in Zambia in 2003 and has ...
... of Naval Research (ONR) will share partnership possibilities with ... Annual Navy Gold Coast Small Business Opportunity Conference, being ... allows us to identify potential program participants from among ... Office of Small Business Programs. "The event is a ...
Cached Biology News:Eco-labeled seafood is not always what it seems 2Study confirms food security helps wildlife 2
(Date:5/17/2013)... May 17, 2013  Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy.  The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board.  In this study, INS001 ...
(Date:5/17/2013)... 2013 The paradigm of ‘one drug, ... that can help predict the adverse and therapeutic effects ... Head of Computational Biology at the Genomics Laboratory, Covance, ... ensure high-quality genomics when used as part of the ... complex data sets to identify key clinical targets even ...
(Date:5/17/2013)... 2013 Rust removal is one of home ... items could be damaged. To help rust contractors make it ... no-scrubbing rust remover it called Rusterizer. It announced ... 10% discount. , My Cleaning Products explained that rust could ... by staining them. The first one, it said, happens ...
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
Breaking Biology Technology:Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... to be Used for Advancement of Cancer Stem Cells and Other ... ... MacroGenics, Inc., a privately,held biotechnology company that develops immunotherapeutics to treat,autoimmune ... million in a Series D-2 financing. The round, led by,Nextech Venture, ...
... COLLINS, Colo., Sept. 24 InVitria,( http://www.InVitria.com ... Annual "Optimizing Cell Culture Development" Conference on,September ... most recent,results optimizing cell culture media using ... ingredients.,( http://www.healthtech.com/ocb/overview.aspx?c=562 ), In a presentation ...
... combats an,alarming rise in chronic diseases, the Pharmaceutical ... new report on the next,generation of medicines in ... The report found that America,s pharmaceutical research ... - are,testing a record 633 new biotech medicines., ...
Cached Biology Technology:MacroGenics Raises $25M in Series D-2 Financing 2MacroGenics Raises $25M in Series D-2 Financing 3MacroGenics Raises $25M in Series D-2 Financing 4InVitria Touts Product Advantages at Cambridge's Cell Culture Conference 2New Report on 633 Biotechnology Medicines Under Development Released in Michigan 2New Report on 633 Biotechnology Medicines Under Development Released in Michigan 3